Hemostemix (TSE:HEM) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Hemostemix has successfully closed the first tranche of its private placement, raising approximately $1.8 million to boost its stem cell therapeutics platform and other operational needs. The funding will support initiatives like the initial sales and processing of angiogenic cell precursors (ACP). Additionally, Hemostemix granted stock options to its directors and officers, furthering its strategic business goals.
For further insights into TSE:HEM stock, check out TipRanks’ Stock Analysis page.
